排序方式： 共有55条查询结果，搜索用时 15 毫秒
1.
2.
3.
4.
Cosmetics are products, which by definition “…must not damage human health in the normal conditions of use”. However, unwanted effects do occur, the best known being cutaneous and allergic reactions. The dermatology-allergy specialist is thus the first to be concerned with cosmetovigilance. In 1966, the Groupe d’études et de recherche en dermato-allergologie (GERDA) created a vigilance network concerned with cutaneous allergic incidents [Réseau de vigilance sur les accidents allergiques cutanés (REVIDAL)], the REVIDAL GERDA, which acts as a coordinator for cosmetovigilance. In 2004, a public cosmetovigilance committee was created; all serious adverse effects or those appearing to be serious were to be reported immediately to the Agence française de sécurité sanitaire des produits de santé (AFSSAPS) by health professionals who observed them. Manufacturers are required to participate in this public cosmetovigilance. They have a similar responsibility via the Direction générale de la concurrence et de la consommation (DGCCRF) to report to AFSSAPS the list of their products which contain substances for which there is a serious doubt. This means that cosmetovigilance requires collection of cases; it will work well only if reports are made regularly. The physician who reports cases improves the management of his patients and participates in Public Health actions. This type of cosmetovigilance will extend to all EU countries. Reports by consumers should be possible, but they will be encouraged to consult a doctor before doing so. 相似文献
5.
Longueville C Doffoel-Hantz V Hantz S Souyri N Nouaille Y Bédane C Sparsa A 《La Revue de médecine interne / fondée ... par la Société nationale francaise de médecine interne》2012,33(3):e17-e18
Erythema nodosum is a panniculitis occurring more frequently in young women. We report a 16-year-old woman who presented with erythema nodosum that occurred following Gardasil® administration (vaccine against HPV types 6, 11, 16 and 18) and that is proposed to young female. This adverse effect is not a contraindication to the HPV vaccination because its benefit against the oncogene risk of Papillomavirus is documented. 相似文献
6.
P. Moncharmont G. Barday H. Odent-Malaure H. Benamara 《Transfusion Clinique et Biologique》2018,25(2):105-108
Objectives
Transfusion in environments other than inpatient hospitalisation requires a specific management of the patient, particularly concerning adverse transfusion reactions. A three-year study was carried out in order to appreciate the nature of adverse transfusion reactions and their incidence in these patients.Material and methods
Adverse transfusion reaction reports of outpatient clinic, ambulatory hospital, health and dialysis centres and home-transfused patients in the Auvergne Rhône Alpes region were obtained. Diagnosis of adverse transfusion reactions, their incidence, their degree of severity, the imputability of the blood component concerned were evaluated.Results
From 1 January 2014 to 31 December 2016, 3,284 reports were notified. Excluding allo-immunisations, 416 reports were obtained, including 376 (90.4%) in outpatient clinic. The febrile non-haemolytic transfusion reaction was the most frequent adverse transfusion reaction (119 cases, 28.6%) followed by allergy (112 cases, 26.9%). A transfusion-associated circulatory overload was notified in 26 cases (6.3%). Among the 416 reports, 363 were non-severe and in 251, a red blood cell concentrate was involved (60.3%). The imputability of the blood product was certain in 50 cases (12.0%) only.Conclusion
With the exception of inpatient hospitalisation and allo-immunisation, the majority of adverse transfusion reactions was notified in outpatient clinic. The febrile non-haemolytic transfusion reaction was the most frequent. 相似文献7.
8.
9.
10.